Everolimus is a potent inhibitor of activated hepatic stellate cell functionsin vitroandin vivo, while demonstrating anti-angiogenic activities

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

(2014) Michael Honer et al.   Translational Oncology

Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis

(2013) Syamantak Majumder et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Early fibrosis inhibits hepatocellular carcinoma mediated by free radical effects

(2013) Nidal Muhanna et al.   MITOCHONDRION

Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C

(2010) G. Svegliati-Baroni et al.   GUT

Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony

(2010) Kathryn G. Foster et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis

(2010) Eleonora Patsenker et al.   JOURNAL OF HEPATOLOGY

Everolimus Interferes with the Inflammatory Phase of Healing in Experimental Colonic Anastomoses

(2009) Markus A. Küper et al.   JOURNAL OF SURGICAL RESEARCH

Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258

(2009) Yuqing Liu et al.   LABORATORY INVESTIGATION

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

(2009) L.-A. Julien et al.   MOLECULAR AND CELLULAR BIOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor- 

(2008) R. A. Rahimi et al.   CANCER RESEARCH